Differential characteristics of the efficacy and tolerability of second-generation antipsychotics in the treatment of psychotic disorders in children and adolescents;Características diferenciales de eficacia y tolerabilidad de los antipsicóticos de segunda generación en el tratamiento de trastornos psicóticos en niños y adolescents

Revista de Psiquiatria y Salud Mental

Volumn 3, Issue 4, 2010, Pages 152-167

  Fraguas, David ^a,b   Merchán Naranjo, Jessica ^b,c   Arango, Celso ^b,c  

^a Hospital de Albacete   (Spain)

^b HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^c CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE SALUD MENTAL CIBERSAM   (Spain)

Author keywords

Antipsychotic; Efficacy; Pediatric population; Psychosis; Tolerability

Indexed keywords

ARIPIPRAZOLE; CHOLESTEROL; NEUROLEPTIC AGENT; OLANZAPINE; PLACEBO; PROLACTIN; QUETIAPINE; RISPERIDONE; VALPROIC ACID;

ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DRUG EFFICACY; DRUG TOLERABILITY; HUMAN; METABOLIC DISORDER; PEDIATRICS; PRESCRIPTION; PROLACTIN BLOOD LEVEL; PSYCHOSIS; SCHIZOPHRENIA; SIDE EFFECT; WEIGHT GAIN;

EID: 78650516562     PISSN: 18889891     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rpsm.2010.08.001     Document Type: Short Survey

References (82)

1. C. Arango, M. Parellada, and D.M. Moreno Clinical effectiveness of new generation antipsychotics in adolescent patients Eur Neuropsychopharmacol 14 Suppl 4 2004 S471 S479
2. R.L. Findling, H. Steiner, and E.B. Weller Use of antipsychotics in children and adolescents J Clin Psychiatry 66 Suppl 7 2005 29 40
3. B. Vitiello, C. Correll, B. Van Zwieten-Boot, A. Zuddas, M. Parellada, and C. Arango Antipsychotics in children and adolescents: increasing use, evidence for efficacy and safety concerns Eur Neuropsychopharmacol 19 2009 629 635
4. M. Olfson, C. Blanco, L. Liu, C. Moreno, and G. Laje National trends in the outpatient treatment of children and adolescents with antipsychotic drugs Arch Gen Psychiatry 63 2006 679 685
5. F. Rani, M.L. Murray, P.J. Byrne, and I.C. Wong Epidemiologic features of antipsychotic prescribing to children and adolescents in primary care in the United Kingdom Pediatrics 121 2008 1002 1009
6. N.C. Patel, M.L. Crismon, K. Hoagwood, M.T. Johnsrud, K.L. Rascati, and J.P. Wilson Trends in the use of typical and atypical antipsychotics in children and adolescents J Am Acad Child Adolesc Psychiatry 44 2005 548 556 (Pubitemid 40720954)
7. L.J. Kalverdijk, H. Tobi, P.B. Van den Berg, J. Buiskool, L. Wagenaar, and R.B. Minderaa Use of antipsychotic drugs among Dutch youths between 1997 and 2005 Psychiatr Serv 59 2008 554 560
8. L. Sikich, J.A. Frazier, J. McClellan, R.L. Findling, B. Vitiello, and L. Ritz Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study Am J Psychiatry 165 2008 1420 1431
9. C.U. Correll Antipsychotic use in children and adolescents: minimizing adverse effects to maximize outcomes J Am Acad Child Adolesc Psychiatry 47 2008 9 20
10. D. Fraguas, J. Merchn-Naranjo, P. Laita, M. Parellada, D. Moreno, and A. Ruiz-Sancho Metabolic and hormonal side effects in children and adolescents treated with second-generation antipsychotics J Clin Psychiatry 69 2008 1166 1175
11. P. Tyrer, and T. Kendall The spurious advance of antipsychotic drug therapy Lancet 373 2009 4 5
12. C.U. Correll, and H.E. Carlson Endocrine and metabolic adverse effects of psychotropic medications in children and adolescents J Am Acad Child Adolesc Psychiatry 45 2006 771 791
13. C.U. Correll, P. Manu, V. Olshanskiy, B. Napolitano, J.M. Kane, and A.K. Malhotra Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents JAMA 302 2009 1765 1773
14. R. Weiss, J. Dziura, T.S. Burgert, W.V. Tamborlane, S.E. Taksali, and C.W. Yeckel Obesity and the metabolic syndrome in children and adolescents N Engl J Med 350 2004 2362 2374
15. D. Fraguas, M.J. de Castro, O. Medina, M. Parellada, D. Moreno, and M. Graell Does diagnostic classification of early-onset psychosis change over follow-up? Child Psychiatry Hum Dev 39 2008 137 145
16. R.L. Findling, A. Robb, M. Nyilas, R.A. Forbes, N. Jin, and S. Ivanova A multiple-center, randomized, double-blind, placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophrenia Am J Psychiatry 165 2008 1432 1441
17. M. Haas, M. Eerdekens, S. Kushner, J. Singer, I. Augustyns, and J. Quiroz Efficacy, safety and tolerability of two dosing regimens in adolescent schizophrenia: double-blind study Br J Psychiatry 194 2009 158 164
18. L. Kryzhanovskaya, S.C. Schulz, C. McDougle, J. Frazier, R. Dittmann, and C. Robertson-Plouch Olanzapine versus placebo in adolescents with schizophrenia: a 6-week, randomized, double-blind, placebo-controlled trial J Am Acad Child Adolesc Psychiatry 48 2009 60 70
19. M. Tohen, L. Kryzhanovskaya, G. Carlson, M. Delbello, J. Wozniak, and R. Kowatch Olanzapine versus placebo in the treatment of adolescents with bipolar mania Am J Psychiatry 164 2007 1547 1556
20. S. Kumra, H. Kranzler, G. Gerbino-Rosen, H.M. Kester, C. De Thomas, and V. Kafantaris Clozapine and "high-dose" olanzapine in refractory early-onset schizophrenia: a 12-week randomized and double-blind comparison Biol Psychiatry 63 2008 524 529
21. S. Kumra, J.V. Oberstar, L. Sikich, R.L. Findling, J.M. McClellan, and S. Vinogradov Efficacy and tolerability of second-generation antipsychotics in children and adolescents with schizophrenia Schizophr Bull 34 2008 60 71
22. P. Shaw, A. Sporn, N. Gogtay, G.P. Overman, D. Greenstein, and P. Gochman Childhood-onset schizophrenia: A double-blind, randomized clozapine-olanzapine comparison Arch Gen Psychiatry 63 2006 721 730
23. C. Arango, O. Robles, M. Parellada, D. Fraguas, A. Ruiz-Sancho, and O. Medina Olanzapine compared to quetiapine in adolescents with a first psychotic episode Eur Child Adolesc Psychiatry 18 2009 418 428
24. J. Castro-Fornieles, M. Parellada, C.A. Soutullo, I. Baeza, A. Gonzlez-Pinto, and M. Graell Antipsychotic treatment in child and adolescent first-episode psychosis: a longitudinal naturalistic approach J Child Adolesc Psychopharmacol 18 2008 327 336
25. D. Gothelf, A. Apter, J. Reidman, A. Brand-Gothelf, Y. Bloch, and G. Gal Olanzapine, risperidone and haloperidol in the treatment of adolescent patients with schizophrenia J Neural Transm 110 2003 545 560
26. L. Sikich, R.M. Hamer, R.A. Bashford, B.B. Sheitman, and J.A. Lieberman A pilot study of risperidone, olanzapine, and haloperidol in psychotic youth: a double-blind, randomized, 8-week trial Neuropsychopharmacology 29 2004 133 145
27. C. Fleischhaker, P. Heiser, K. Hennighausen, B. Herpertz-Dahlmann, K. Holtkamp, and C. Mehler-Wex Weight gain associated with clozapine, olanzapine and risperidone in children and adolescents J Neural Transm 114 2007 273 280
28. C. Fleischhaker, P. Heiser, K. Hennighausen, B. Herpertz-Dahlmann, K. Holtkamp, and C. Mehler-Wex Weight gain in children and adolescents during 45 weeks treatment with clozapine, olanzapine and risperidone J Neural Transm 115 2008 1599 1608
29. V.J. Fedorowicz, and E. Fombonne Metabolic side effects of atypical antipsychotics in children: a literature review J Psychopharmacol 19 2005 533 550
30. K.A. Stigler, M.N. Potenza, and C.J. McDougle Tolerability profile of atypical antipsychotics in children and adolescents Paediatr Drugs 3 2001 927 942
31. W.V. Vieweg, A.B. Sood, A. Pandurangi, and J.J. Silverman Newer antipsychotic drugs and obesity in children and adolescents. How should we assess drug-associated weight gain? Acta Psychiatr Scand 111 2005 177 184
32. Y. Roke, P.N. Van Harten, A.M. Boot, and J.K. Buitelaar Antipsychotic medication in children and adolescents: a descriptive review of the effects on prolactin level and associated side effects J Child Adolesc Psychopharmacol 19 2009 403 414
33. Pappagallo M, Silva R. The effect of atypical antipsychotic agents on prolactin levels in children and adolescents. J Child Adolesc Psychopharmacol. 2004 Fall;14:35971.
34. M.A. Richardson, G. Haugland, and T.J. Craig Neuroleptic use, parkinsonian symptoms, tardive dyskinesia, and associated factors in child and adolescent psychiatric patients Am J Psychiatry 148 1991 1322 1328
35. J. Cheng-Shannon, J.J. McGough, C. Pataki, and J.T. McCracken Second-generation antipsychotic medications in children and adolescents J Child Adolesc Psychopharmacol. Fall 14 2004 372 394
36. I.D. Glick, S.R. Murray, P. Vasudevan, S.R. Marder, and R.J. Hu Treatment with atypical antipsychotics: new indications and new populations J Psychiatr Res 35 2001 187 191
37. P.S. Jensen, J. Buitelaar, G.J. Pandina, C. Binder, and M. Haas Management of psychiatric disorders in children and adolescents with atypical antipsychotics: a systematic review of published clinical trials Eur Child Adolesc Psychiatry 16 2007 104 120
38. C.U. Correll, and J.M. Kane One-year incidence rates of tardive dyskinesia in children and adolescents treated with second-generation antipsychotics: a systematic review J Child Adolesc Psychopharmacol 17 2007 647 656
39. P. Toren, S. Ratner, N. Laor, and A. Weizman Benefit-risk assessment of atypical antipsychotics in the treatment of schizophrenia and comorbid disorders in children and adolescents Drug Saf 27 2004 1135 1156
40. R.S. McIntyre, and J.M. Jerrell Metabolic and cardiovascular adverse events associated with antipsychotic treatment in children and adolescents Arch Pediatr Adolesc Med 162 2008 929 935
41. M. Harrison-Woolrych, J. Garcia-Quiroga, J. Ashton, and P. Herbison Safety and usage of atypical antipsychotic medicines in children: a nationwide prospective cohort study Drug Saf 30 2007 569 579
42. C.U. Correll, E.M. Sheridan, and M.P. DelBello Antipsychotic and mood stabilizer efficacy and tolerability in pediatric and adult patients with bipolar I mania: a comparative analysis of acute, randomized, placebo-controlled trials Bipolar Disord 12 2010 116 141
43. M.K. Singh, T.A. Ketter, and K.D. Chang Atypical antipsychotics for acute manic and mixed episodes in children and adolescents with bipolar disorder: efficacy and tolerability Drugs 70 2010 433 442
44. M.P. DelBello, and C.U. Correll Primum non nocere: balancing the risks and benefits of prescribing psychotropic medications for youth with bipolar disorder Bipolar Disord 12 2010 113 115
45. R.L. Findling, and N.K. McNamara Atypical antipsychotics in the treatment of children and adolescents: clinical applications J Clin Psychiatry 65 Suppl 6 2004 30 44
46. S. Leucht, C. Corves, D. Arbter, R.R. Engel, C. Li, and J.M. Davis Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis Lancet 373 2009 31 41
47. V. Burke Obesity in childhood and cardiovascular risk Clin Exp Pharmacol Physiol 33 2006 831 837
48. S.M. Stahl, L. Mignon, and J.M. Meyer Which comes first: atypical antipsychotic treatment or cardiometabolic risk? Acta Psychiatr Scand 119 2009 171 179
49. Moreno CM-NJ, lvarez M, Baeza I, Alda JA, Martnez-Cantarero C, Parellada M, Snchez B, De la Serna E, Girldez M, Arango C. Metabolic effects of second-generation antipsychotics in bipolar youth: comparison with other psychotic and non-psychotic diagnoses. Bipolar Disroder. En prensa.
50. V. Simon, R. Van Winkel, and M. De Hert Are weight gain and metabolic side effects of atypical antipsychotics dose dependent? A literature review J Clin Psychiatry 70 2009 1041 1050
51. Alfaro CL, Wudarsky M, Nicolson R, Gochman P, Sporn A, Lenane M, et al. Correlation of antipsychotic and prolactin concentrations in children and adolescents acutely treated with haloperidol, clozapine, or olanzapine. J Child Adolesc Psychopharmacol. 2002 Summer;12:8391.
52. M. Haas, A.S. Unis, J. Armenteros, M.D. Copenhaver, J.A. Quiroz, and S.F. Kushner A 6-week, randomized, double-blind, placebo-controlled study of the efficacy and safety of risperidone in adolescents with schizophrenia J Child Adolesc Psychopharmacol 19 2009 611 621
53. R. Prez-Iglesias, B. Crespo-Facorro, O. Martnez-Garca, M.L. Ramrez-Bonilla, M. lvarez-Jimnez, and J.M. Pelayo-Tern Weight gain induced by haloperidol, risperidone and olanzapine after 1 year: findings of a randomized clinical trial in a drug-naive population Schizophr Res 99 2008 13 22
54. P. Laita, A. Cifuentes, A. Doll, C. Llorente, I. Cortes, and M. Parellada Antipsychotic-related abnormal involuntary movements and metabolic and endocrine side effects in children and adolescents J Child Adolesc Psychopharmacol 17 2007 487 502
55. J.M. Davis, N. Chen, and I.D. Glick A meta-analysis of the efficacy of second-generation antipsychotics Arch Gen Psychiatry 60 2003 553 564
56. S. Leucht, K. Komossa, C. Rummel-Kluge, C. Corves, H. Hunger, and F. Schmid A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia Am J Psychiatry 166 2009 152 163
57. H. Carmel, and J.M. Gorman Classifying antipsychotics by likelihood of metabolic side-effects Psychiatr Serv 60 2009 1143
58. T.A. Cohn, and M.J. Sernyak Metabolic monitoring for patients treated with antipsychotic medications Can J Psychiatry 51 2006 492 501
59. E.H. Morrato, B. Druss, D.M. Hartung, R.J. Valuck, R. Allen, and E. Campagna Metabolic testing rates in 3 state Medicaid programs after FDA warnings and ADA/APA recommendations for second-generation antipsychotic drugs Arch Gen Psychiatry 67 2010 17 24
60. L. Bastiaens A non-randomized, open study with aripiprazole and ziprasidone for the treatment of aggressive behavior in youth in a community clinic Community Ment Health J 45 2009 73 77
61. M.P. Delbello, M.L. Schwiers, H.L. Rosenberg, and S.M. Strakowski A double-blind, randomized, placebo-controlled study of quetiapine as adjunctive treatment for adolescent mania J Am Acad Child Adolesc Psychiatry 41 2002 1216 1223
62. M.P. DelBello, K. Chang, J.A. Welge, C.M. Adler, M. Rana, and M. Howe A double-blind, placebo-controlled pilot study of quetiapine for depressed adolescents with bipolar disorder Bipolar Disord 11 2009 483 493
63. R.L. Findling, M. Nyilas, R.A. Forbes, R.D. McQuade, N. Jin, and T. Iwamoto Acute treatment of pediatric bipolar I disorder, manic or mixed episode, with aripiprazole: a randomized, double-blind, placebo-controlled study J Clin Psychiatry 70 2009 1441 1451
64. M. Haas, M.P. Delbello, G. Pandina, S. Kushner, I. Van Hove, and I. Augustyns Risperidone for the treatment of acute mania in children and adolescents with bipolar disorder: a randomized, double-blind, placebo-controlled study Bipolar Disord 11 2009 687 700
65. J.B. Jensen, S. Kumra, W. Leitten, J. Oberstar, A. Anjum, and T. White A comparative pilot study of second-generation antipsychotics in children and adolescents with schizophrenia-spectrum disorders J Child Adolesc Psychopharmacol 18 2008 317 326
66. S. Kumra, J.A. Frazier, L.K. Jacobsen, K. McKenna, C.T. Gordon, and M.C. Lenane Childhood-onset schizophrenia. A double-blind clozapine-haloperidol comparison Arch Gen Psychiatry 53 1996 1090 1097
67. T. Mozes, T. Ebert, S.E. Michal, B. Spivak, and A. Weizman An open-label randomized comparison of olanzapine versus risperidone in the treatment of childhood-onset schizophrenia J Child Adolesc Psychopharmacol 16 2006 393 403
68. H.S. Swadi, B.J. Craig, N.Z. Pirwani, V.C. Black, J.C. Buchan, and C.M. Bobier A trial of quetiapine compared with risperidone in the treatment of first onset psychosis among 15- to 18-year-old adolescents Int Clin Psychopharmacol 25 2010 1 6
69. S. Tramontina, C.P. Zeni, C.R. Ketzer, G.F. Pheula, J. Narvaez, and L.A. Rohde Aripiprazole in children and adolescents with bipolar disorder comorbid with attention-deficit/hyperactivity disorder: a pilot randomized clinical trial J Clin Psychiatry 70 2009 756 764
70. J. Biederman, E. Mick, P. Hammerness, T. Harpold, M. Aleardi, and M. Dougherty Open-label, 8-week trial of olanzapine and risperidone for the treatment of bipolar disorder in preschool-age children Biol Psychiatry 58 2005 589 594
71. C. Fleischhaker, P. Heiser, K. Hennighausen, B. Herpertz-Dahlmann, K. Holtkamp, and C. Mehler-Wex Clinical drug monitoring in child and adolescent psychiatry: side effects of atypical neuroleptics J Child Adolesc Psychopharmacol 16 2006 308 316
72. M. Hrdlicka, I. Zedkova, M. Blatny, and T. Urbanek Weight gain associated with atypical and typical antipsychotics during treatment of adolescent schizophrenic psychoses: A retrospective study Neuro Endocrinol Lett 30 2009 256 261
73. R.A. Khan, L.M. Mican, and B.T. Suehs Effects of olanzapine and risperidone on metabolic factors in children and adolescents: a retrospective evaluation J Psychiatr Pract 15 2009 320 328
74. G. Migliardi, E. Spina, C. D'Arrigo, A. Gagliano, E. Germano, and R. Siracusano Short- and long-term effects on prolactin of risperidone and olanzapine treatments in children and adolescents Prog Neuropsychopharmacol Biol Psychiatry 33 2009 1496 1501
75. G. Ratzoni, D. Gothelf, A. Brand-Gothelf, J. Reidman, L. Kikinzon, and G. Gal Weight gain associated with olanzapine and risperidone in adolescent patients: a comparative prospective study J Am Acad Child Adolesc Psychiatry 41 2002 337 343
76. Saito E, Correll CU, Gallelli K, McMenimun M, Parikh UH, Malhotra AK, et al. A prospective study of hyperprolactinemia in children and adolescents treated with atypical antipsychotic agents. J Child Adolesc Psychopharmacol. 2004 Fall;14:3508.
77. J.R. Stevens, P.I. Kymissis, and A.J. Baker Elevated prolactin levels in male youths treated with risperidone and quetiapine J Child Adolesc Psychopharmacol 15 2005 893 900
78. M. Wudarsky, R. Nicolson, S.D. Hamburger, L. Spechler, P. Gochman, and J. Bedwell Elevated prolactin in pediatric patients on typical and atypical antipsychotics J Child Adolesc Psychopharmacol 9 1999 239 245
79. Guy W. ECDEU Assessment Manual for Psychopharmacology, edicin revisada. Washington, DC, US Department of Health, Education, and Welfare, 1976.
80. T.R. Barnes The Barnes Akathisia Rating Scale - revisited J Psychopharmacol 17 2003 365 370
81. G.M. Simpson, and J.W. Angus A rating scale for extrapyramidal side effects Acta Psychiatr Scand Suppl 212 1970 11 19
82. O. Lingjaerde, U.G. Ahlfors, P. Bech, S.J. Dencker, and K. Elgen The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients Acta Psychiatr Scand Suppl 334 1987 1 100